Nelson Sabates, MD
Ophthalmology · Leawood, KSNPI 1285632356
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,177 of the $1,341 with a category attached, or 87.8%. 15 manufacturers reported payments, led by Alcon at 53.3% of the total. That places this record below the midpoint for ophthalmology clinicians in KS, where the typical reported total is $1,383.
Across 33 payments — averaging $40.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$714
- Bausch & Lomb Americas Inc.$154
- Optos, Inc.$104
- Genentech USA, Inc.$64
- Glaukos Corporation$47
- Carl Zeiss Meditec USA, Inc.$40
- plus $217 from 9 others
Across 24 payments — averaging $3364.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$33K
- Genentech, Inc.$24K
- Hexal AG$17K
- Regeneron$6K
What the payments were for
- Travel & lodging$121%
- Food & beverage$1,17788%
- Gifts$484%
- Entertainment$1048%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 12 | $714 |
| Bausch & Lomb Americas Inc. | 3 | $154 |
| Optos, Inc. | 1 | $104 |
| Genentech USA, Inc. | 3 | $64 |
| Glaukos Corporation | 1 | $47 |
| Carl Zeiss Meditec USA, Inc. | 2 | $40 |
| Apellis Pharmaceuticals, Inc. | 2 | $36 |
| Rxsight Inc | 2 | $36 |
| Carl Zeiss Meditec, Inc. | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| AbbVie | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$237
- PANORAMIC OPHTHALMOSCOPE$209
- OCT OPHTHALMOSCOPE$209
- ARGOS$132
- NFC-700$104
- AcrySof IQ PanOptix$101
How this compares
$1,341 in reported general payments places this provider in the 45th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 28 | $12,079 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $5,882 |
| Prednisolone Acetate | 221 | $5,838 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $2,259 |
| Ofloxacin | 184 | $1,846 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $1,082 |
| Latanoprost | 61 | $687 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $578 |
| Ketorolac Tromethamine | 18 | $353 |
| Timolol Maleate | 14 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $17 | $17,96252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Leawood
- John DoaneLeawood$496K
- Matthew SniegowskiLeawood$22K
- Timothy WallineLeawood$5K
- Alaina GerenLeawood$4K
- Kevin PikeyLeawood$3K
- Alexander VuLeawood$2K
- Daniel DurrieOverland Park$974K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Blake CooperLenexa$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.